HOXA10

Across TCGA pan-cancer cohorts, HOXA10 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HOXA10 data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HOXA10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HOXA10 expression acts as an unfavorable survival marker.

LIHC, CESC, and UCEC are the cancer types where HOXA10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.098	0.774	.001	9	view →
CESC	DFS	Median	IV	0.053	0.529	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	DFS	Median	II,III,IV	0.164	0.561	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HOXA10–LIHC (OS)

Open the LIHC breakdown →